Tagged with Merck,

Global As pharma navigates issues ranging from the US Inflation Reduction Act to new EU pharmaceutical legislation, and the impact of global unrest on supply chains, the industry is experiencing other shifts as reflected in Pharma Exec’s 2024 Top 50 Companies. Based on 2023 drug revenue performance from global drug makers,…

Hong Kong Tony Cheng, managing director and general manager for Hong Kong & Macau at Merck Healthcare walks us through the challenges and opportunities arising from Hong Kong’s transformation, Merck’s strong local presence, its collaboration with the Hong Kong Science and Technology Park to support local start-ups, the affiliate’s engagement in the…

Germany A roundup of some of the biggest stories coming out of German pharma, including Merck’s better-than-expected Q1 earnings; Stada’s possible return to the stock market; CDMO Vetter’s expanded capacity in the US and Germany; Bayer’s elimination of some 1,500 jobs, and BioNTech’s bid for MediLink’s solid tumour platform.   Merck…

Korea A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new 300-million-euro plant; EuBiologics’s World Health Organization (WHO) prequalification for its cholera vaccine, and Samsung Biologics’ record Q1 earnings.   South…

Mexico The latest stories from Mexican pharma and healthcare, including Sanfer’s purchase of Colombia-based manufacturer Vitalis; Organon Mexico’s new business; the FDA’s warning to Glicerinas Industriales, and a look at the issues, including health, the new Mexican president will have to face.   Mexico’s Health Ministry issues measles alert (Mexico News) Mexico’s…

LatAm A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s acquisition of 30% of Argentina’s Tuteur, and Urufarma’s new manufacturing facility in Uruguay.   Merck to open new distribution centre…

Germany The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion into the US; the antibody-drug conjugate (ADC) specialist Tubulis’ series B2 financing, and Novartis’ deal with biotech MorphoSys.   Germany’s…

Portugal Diabetes is a rising threat to the Portuguese people, the country’s healthcare system, and its economy. Portugal’s National Diabetes Observatory observed that 1.1 million Portuguese people between the ages of 20 and 79.5 (out of a total population of just 10.3 million) were living with diabetes in 2021.   This…

India Multinational life science firms have been present in India for decades. However, they have often eschewed bringing their latest products to a country that has long prioritised affordability above innovation. Now though, as India’s GDP and market value soar and the policy environment shifts towards prioritising the domestic development of…

Global Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found herself out of a job.  Now, after joining the boards of several biotechs, including Galapagos, Schaffert returns to big pharma,…

Portugal Portugal boasts a well-developed universal healthcare system and saw healthcare spending increase by 6.2 percent annually between 2016 and 2021, according to the OECD. However, the representatives of innovative medicines manufacturers embedded in the country are keen to point out that access to the latest drugs remains a big issue…

India Pratima Reddy, GM at Merck Healthcare India reviews the importance of Merck’s Indian affiliate, discusses the recent reforms that have contributed both to improving patient access and to fostering foreign investments and innovation, and explains the representation of Merck’s portfolio in the country, and how the company navigates the local…